Drilldown: Medicines

Finasteride (1) · Lactulose (1) · Linagliptin (1)

Kristalose, Constulose, Generlac, Enulose (1) · Proscar (5 mg, BPH), Propecia (1 mg, alopecia) (1) · Tradjenta; with metformin Jentadueto (1)

[[:Category:5-alpha-reductase_inhibitors|5α-reductase inhibitor]] (1) · [[:Category:Androgen_modulators|Androgen modulator]] (1) · [[:Category:Antihyperglycemic_agents|Antihyperglycemic agent]] (1) · [[:Category:BPH_treatments|Benign prostatic hyperplasia treatment]] (1) · [[:Category:Disaccharides|Non-absorbable disaccharide]] (1) · [[:Category:DPP-4_inhibitors|DPP-4 inhibitor]] (1) · [[:Category:Hepatic_encephalopathy_treatments|Hepatic encephalopathy treatment]] (1) · [[:Category:Incretin_modulators|Incretin pathway modulator]] (1) · [[:Category:Osmotic_laxatives|Osmotic laxative]] (1)

None (3)

'"`UNIQ--vote-0000052E-QINU`"', '"`UNIQ--vote-0000052F-QINU`"', '"`UNIQ--vote-00000530-QINU`"' (1) · '"`UNIQ--vote-00000F5C-QINU`"', '"`UNIQ--vote-00000F5D-QINU`"' (1) · '"`UNIQ--vote-0000117B-QINU`"' (1)

5 mg PO daily for BPH; 1 mg PO daily for androgenetic alopecia (1) · 5 mg PO once daily (no renal dose adjustment, unlike sitagliptin) (1) · Constipation: 15-30 mL PO daily (titrate to 1-2 soft stools/day); hepatic encephalopathy: 20-30 g (30-45 mL) PO/PR every 1-2 hours acutely until soft stools, then BID-QID to target 2-3 soft stools/day (1)

1 mg, 5 mg tablets (1) · 10 g/15 mL solution (Constulose); 10 g, 20 g powder packets (Kristalose) (1) · 5 mg tablets; combination with metformin (1)

None · Indication-specific · 40 mg/d · 10 mg/d · 20 mg/d · 80 mg/d · 10 mg/d (adults) · 100 mg/d · 4 g/d · 400 mg/d · 40 mg/d typical; up to 240 mg/d for Zollinger-Ellison · 5 mg/d · 50 mg/d · 600 mg/d · No fixed ceiling; titrate to clinical effect and tolerability with CDC opioid prescribing guidance constraints on morphine-milligram-equivalent (MME) totals · No fixed maximum; titrated to TSH target · TID per eye · Titrated to glucose; no fixed ceiling · Titrated to glucose; no fixed maximum · '''20 mg/day in adults >60 years''' per FDA's 2011-2012 QT-prolongation warning; 40 mg/day in adults ≤60

Other values:

Search

especially in acute HE) (1) · Oral (3) · rectal (enema (1)

BPH symptom improvement at 3-6 months; prostate volume reduction over 6-12 months; hair regrowth at 6-12 months (1) · Constipation: 24-48 hours; HE: ammonia reduction within hours of stool production (1) · Postprandial glucose effect within days; HbA1c by 12 weeks (1)

24 hours (2) · Hours (1)

Not meaningfully described — lactulose is not significantly absorbed (1) · ~12 hours (effective); terminal much longer'"`UNIQ--ref-0000117C-QINU`"' (1) · ~5-6 hours in young men, ~8 hours in elderly'"`UNIQ--ref-00000531-QINU`"' (1)

<3% systemic absorption (the basis of the safety and mechanism)'"`UNIQ--ref-00000F5E-QINU`"' (1) · ~30% (oral)'"`UNIQ--ref-0000117D-QINU`"' (1) · ~63% (oral)'"`UNIQ--ref-00000532-QINU`"' (1)

'''Pregnant individuals should not handle crushed/broken tablets''' (skin absorption risk); can cause hypospadias in male fetus. Not used in pregnancy.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Generally considered safe (minimal systemic absorption).<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Limited data; switch to insulin where feasible.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)

[[USLegal:Prescription only|Rx-only]] in US (3)